Latest Opioid Stories
Programs encouraging appropriate use of painkillers could improve safety, reduce costs ST.
JUPITER, Fla., April 6, 2015 /PRNewswire/ -- Charleston Laboratories, Inc.
Cash Payment Resulting from First Commercial Sale of MOVANTIK(TM) (naloxegol) Tablets in the US SAN FRANCISCO, April 2, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced
In the news release, Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020, issued 01-Apr-2015 by Egalet Corporation over PR Newswire, we
WAYNE, Pa., April 1, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing
WILMINGTON, Del., March 31, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca announced today that MOVANTIK(TM) (naloxegol) has launched in the United States.
FLORHAM PARK, N.J., March 30, 2015 /PRNewswire/ -- Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met
--Company to host conference call today at 8:00 AM EDT-- WAYNE, Pa., March 25, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical
Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations NEW YORK, March 24, 2015 /PRNewswire/ -- Relmada
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
- The parings of haberdine; also, any kind of fragments.